Cargando…

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

PURPOSE: To assess the immunomodulatory and clinical effects of lenalidomide with standard treatment of gemcitabine in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ullenhag, Gustav J., Mozaffari, Fariba, Broberg, Mats, Mellstedt, Håkan, Liljefors, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242484/ https://www.ncbi.nlm.nih.gov/pubmed/28099502 http://dx.doi.org/10.1371/journal.pone.0169736

Ejemplares similares

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2015)

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
por: Eriksson, Emma, et al.
Publicado: (2016)

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
por: Palma, Marzia, et al.
Publicado: (2017)

Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
por: Kordes, Maximilian, et al.
Publicado: (2019)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

Is gemcitabine (GEM)-based combination therapy good for the treatment of advanced pancreatic cancer?
por: Hao, Fulong, et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
por: Blomstrand, Hakon, et al.
Publicado: (2020)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma
por: Mosavi, Firas, et al.
Publicado: (2013)

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients
por: Corrie, P, et al.
Publicado: (2002)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Liu, Yanfeng, et al.
Publicado: (2022)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Cancer treatment of today in view of the Nobel Prize
por: Ullenhag, Gustav
Publicado: (2018)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
por: Habib, Saffiya, et al.
Publicado: (2021)

Retracted: Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
por: Nakai, Y, et al.
Publicado: (2012)

The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Zhaohuan, et al.
Publicado: (2022)

Phase II study of gemcitabine in patients with advanced pancreatic cancer.
por: Carmichael, J., et al.
Publicado: (1996)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
por: Huang, Jun-Hao, et al.
Publicado: (2023)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer
por: Fiore, Michele, et al.
Publicado: (2015)

A Phase II Study of Pelareorep (REOLYSIN(®)) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
por: Mahalingam, Devalingam, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
por: Kokhaei, Parviz, et al.
Publicado: (2018)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_95qqisehg8cc1n90biapod9ftk